OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -37.31%67.48M | 24.78%24.07M | -77.96%9.37M | 38.56%28.29M | -77.38%5.75M | 311.59%107.64M | 13.25%19.29M | 177.82%42.5M | 2,137.92%20.42M | 591.40%25.43M |
Net income from continuing operations | -41.41%37.11M | 65.56%10.45M | -49.18%7.7M | -54.23%9.37M | -55.17%9.6M | 16.43%63.34M | -61.74%6.31M | 27.39%15.15M | 49.14%20.46M | 74.12%21.42M |
Operating gains losses | 29.46%-1.75M | 1,009.52%191K | 96.52%-87K | -132.14%-9K | -11,618.75%-1.84M | -1,091.20%-2.48M | -137.50%-21K | -1,463.13%-2.5M | -82.17%28K | -91.88%16K |
Depreciation and amortization | 10.13%20.83M | -8.73%4.85M | 14.75%5.32M | 11.88%5.25M | 26.64%5.41M | 15.12%18.91M | -14.90%5.31M | 39.95%4.64M | 21.70%4.69M | 41.51%4.28M |
Deferred tax | 148.57%1.08M | 577.02%4.1M | -33.05%-1.1M | -217.46%-1.53M | 74.77%-386K | 15.96%-2.23M | 140.15%605K | -157.28%-826K | 76.28%-481K | -171.76%-1.53M |
Other non cash items | 177.75%828K | 97.65%-171K | -74.93%532K | -135.42%-763K | -36.66%1.23M | 83.37%-1.07M | -226.30%-7.28M | 554.39%2.12M | 7,327.59%2.15M | 152.01%1.94M |
Change In working capital | -84.08%2.34M | -121.55%-428K | -116.04%-3.63M | 284.41%15.05M | -391.92%-8.65M | 128.53%14.7M | 125.71%1.99M | 358.77%22.63M | 53.71%-8.16M | 89.91%-1.76M |
-Change in receivables | -151.33%-8.71M | ---- | ---- | ---- | ---- | 160.50%16.97M | ---- | ---- | ---- | ---- |
-Change in inventory | 237.00%6.78M | ---- | ---- | ---- | ---- | 86.61%-4.95M | ---- | ---- | ---- | ---- |
-Change in prepaid assets | -166.90%-3.99M | ---- | ---- | ---- | ---- | 18.02%5.96M | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | 573.41%9.19M | ---- | ---- | ---- | ---- | -84.33%1.37M | ---- | ---- | ---- | ---- |
-Change in other working capital | 79.81%-938K | ---- | ---- | ---- | ---- | -1,781.38%-4.65M | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -37.31%67.48M | 24.78%24.07M | -77.96%9.37M | 38.56%28.29M | -77.38%5.75M | 311.59%107.64M | 13.25%19.29M | 177.82%42.5M | 2,137.92%20.42M | 591.40%25.43M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 72.41%-12.36M | 42.75%-4.63M | 54.44%-3.45M | 47.38%-3.6M | 96.95%-681K | 4.20%-44.79M | 56.64%-8.09M | 33.45%-7.56M | -17.99%-6.84M | -103.91%-22.3M |
Capital expenditure reported | 58.53%-14.65M | 58.23%-3.43M | 64.05%-3.57M | 57.76%-3.73M | 53.08%-3.92M | 12.97%-35.33M | 46.74%-8.21M | 12.54%-9.94M | -52.20%-8.83M | -4.26%-8.35M |
Net PPE purchase and sale | 31.28%3.45M | -131.20%-39K | -94.62%128K | 2,460.00%128K | 2,510.48%3.24M | -16.98%2.63M | 941.67%125K | --2.38M | --5K | -96.07%124K |
Net business purchase and sale | --0 | --0 | --0 | --0 | --0 | 25.54%-12.09M | --0 | --0 | --1.98M | -8.30%-14.07M |
Net investment purchase and sale | ---1.16M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 72.41%-12.36M | 42.75%-4.63M | 54.44%-3.45M | 47.38%-3.6M | 96.95%-681K | 4.20%-44.79M | 56.64%-8.09M | 33.45%-7.56M | -17.99%-6.84M | -103.91%-22.3M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 2.29%-47.8M | -107.38%-7M | 78.46%-7.3M | -827.30%-21.84M | -25.35%-11.67M | -317.02%-48.92M | -142.75%-3.38M | -3,737.37%-33.88M | -646.40%-2.36M | -161.64%-9.31M |
Net issuance payments of debt | -17.00%-32.86M | -179.68%-5.73M | 83.73%-4.18M | -502.55%-17.81M | -7.89%-5.14M | -189.74%-28.09M | -120.24%-2.05M | -1,439.83%-25.7M | 203.08%4.43M | -126.77%-4.77M |
Net common stock issuance | 49.84%-8.39M | 14.90%-297K | 70.37%-2.13M | 90.19%-568K | -59.29%-5.39M | -259.05%-16.73M | 71.01%-349K | -305.35%-7.2M | -579,200.00%-5.79M | -101.61%-3.39M |
Cash dividends paid | 0.73%-4.08M | 0.10%-979K | 0.00%-983K | 0.51%-984K | 2.08%-1.13M | -0.17%-4.11M | 3.35%-980K | 4.00%-983K | 3.98%-989K | -11.93%-1.15M |
Net other financing activities | ---2.47M | --0 | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 2.29%-47.8M | -107.38%-7M | 78.46%-7.3M | -827.30%-21.84M | -25.35%-11.67M | -317.02%-48.92M | -142.75%-3.38M | -3,737.37%-33.88M | -646.40%-2.36M | -161.64%-9.31M |
Net cash flow | ||||||||||
Beginning cash position | 43.95%53.61M | 8.60%47.5M | 9.88%47.42M | 44.25%45.86M | 43.95%53.61M | 2.29%37.24M | 41.32%43.74M | 43.37%43.16M | -8.20%31.79M | 2.29%37.24M |
Current changes in cash | -47.46%7.32M | 58.95%12.44M | -230.49%-1.38M | -74.55%2.86M | -6.84%-6.59M | 617.67%13.93M | 24.73%7.82M | -65.38%1.06M | 276.19%11.22M | -510.48%-6.17M |
Effect of exchange rate changes | -251.03%-3.68M | -231.30%-2.69M | 402.50%1.45M | -984.25%-1.29M | -259.39%-1.15M | 320.04%2.44M | 11,277.78%2.05M | 78.22%-480K | -92.08%146K | 194.64%724K |
End cash Position | 6.78%57.24M | 6.78%57.24M | 8.60%47.5M | 9.88%47.42M | 44.25%45.86M | 43.95%53.61M | 43.95%53.61M | 41.32%43.74M | 43.37%43.16M | -8.20%31.79M |
Free cash flow | -26.94%52.83M | 86.35%20.64M | -82.21%5.79M | 111.89%24.57M | -89.26%1.84M | 600.59%72.31M | 588.68%11.07M | 727.94%32.56M | 270.47%11.59M | 229.53%17.08M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |